Conversations With Cancer Experts About Novel Delivery Options With Checkpoint Inhibitors (ICIs) cover art

Conversations With Cancer Experts About Novel Delivery Options With Checkpoint Inhibitors (ICIs)

Conversations With Cancer Experts About Novel Delivery Options With Checkpoint Inhibitors (ICIs)

By: Annenberg Center for Health Sciences
Listen for free

About this listen

 Immune checkpoint inhibitors (ICIs) have transformed oncology but IV administration can cause infusion reactions, require line access, and add staff and chair-time burden. Recently, atezolizumab and nivolumab were approved for subcutaneous use, with more in development. In this podcast, oncologists Lucio Gordan, MD, and Saby George, MD, discuss the burden of IV ICIs, how subcutaneous options address these issues, compare efficacy and safety, and highlight the role of multidisciplinary teams in treatment decisions and workflow optimization.Annenberg Center for Health Sciences Hygiene & Healthy Living Physical Illness & Disease
Episodes
  • Summary of Key Concepts

    Summary of Key Concepts
    Jul 31 2025
    • Subcutaneous ICI products may offer significant time savings for patients, caregivers, and health care facilities with shorter compounding, administration, and chair time
    • With multiple ICI therapies now approved for subcutaneous injection and more under development, it is vital for institutions to develop interprofessional/multidisciplinary approaches and workflows to integrate novel therapies


    Show More Show Less
    8 mins
  • Interprofessional, Multidisciplinary Collaboration Strategies for Novel Immune-Checkpoint Inhibitor Delivery Systems

    Interprofessional, Multidisciplinary Collaboration Strategies for Novel Immune-Checkpoint Inhibitor Delivery Systems
    Jul 31 2025
    • SC products offer convenient and safe options for patients that may be preferred by patients
    • Effective communication among interprofessional, multidisciplinary team and patients/caregivers is crucial to success and streamlining processes
    • Training is required for providers and staff related to operational, clinical, and financial considerations of SC products
    Show More Show Less
    23 mins
  • Treatment Strategies with ICIs (Efficacy and Safety Data for SC Products)

    Treatment Strategies with ICIs (Efficacy and Safety Data for SC Products)
    Jul 30 2025
    • Atezolizumab and nivolumab are both FDA approved as SC products (pembrolizumab pending approval)
    • Overall safety and efficacy of SC ICI products are similar to IV ICI counterpart therapies
    • Patients receiving SC ICI may experience mild injection site reactions
    • Clinical guidelines (NCCN) recommend
    Show More Show Less
    8 mins
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.